EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeserbriefNetzwerk-Metaanalyse

Beta‐Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random‐Effects Meta‐Analysis

Nicholas M Muller iD, Samuel X Tan iD, Nisal Vipulaguna iD, Chenhao Zhou iD, Maria Celia B Hughes iD, H Peter Soyer iD, Lena von Schuckmann iD, Kiarash Khosrotehrani iD

Pigment Cell & Melanoma Research · 2025-01 · 38 (1)

DOI: 10.1111/pcmr.13225 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 13.01.2025. Verfasst von Nicholas M Muller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Cancer Council Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beta‐blockers have generated an exciting discourse for their potential as a cheap, safe, and effective adjunctive therapy for cutaneous melanoma patients, but the field remains murky. This systematic review investigates the association between beta‐blocker use and survival outcomes in cutaneous melanoma patients. We reviewed 12 studies with 21,582 patients in a network meta‐analysis and found a benefit between beta‐blocker use and disease‐free survival but no other significant association for melanoma‐specific or overall survival. However, some evidence suggests that pan‐selective beta‐blockers, rather than cardio‐selective ones, may have a protective effect. We conclude that the current evidence is insufficient to recommend beta‐blockers for melanoma treatment but suggest further research focusing on pan‐selective beta‐blockers to clarify their potential benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsAdrenergic beta-AntagonistsHumansTreatment OutcomeCutaneous Malignant MelanomaDisease-Free Survival

Stichwörter der Autor:innen

adjuvant therapybeta‐blockersdisease‐free survivaldrug repurposingmelanomameta‐analysispropranololskin cancer

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
  • Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia.
  • Department of Dermatology, Sunshine Coast University Hospital, Birtinya, Australia.

ORCID-Profile: Nicholas M Muller, Samuel X Tan, Nisal Vipulaguna, Chenhao Zhou, Maria Celia B Hughes, H Peter Soyer, Lena von Schuckmann, Kiarash Khosrotehrani

Förderung

  • Cancer Council Queensland

Zitieren

APA

Muller, N. M., Tan, S. X., Vipulaguna, N., Zhou, C., Hughes, M. C. B., Soyer, H. P., von Schuckmann, L., & Khosrotehrani, K. (2025). Beta‐Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random‐Effects Meta‐Analysis. Pigment Cell & Melanoma Research, 38(1). https://doi.org/10.1111/pcmr.13225

Vancouver

Muller NM, Tan SX, Vipulaguna N, Zhou C, Hughes MCB, Soyer HP, et al. Beta‐Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random‐Effects Meta‐Analysis. Pigment Cell & Melanoma Research. 2025;38(1). doi:10.1111/pcmr.13225

BibTeX
@article{Muller2025,
  author = {Muller, Nicholas M and Tan, Samuel X and Vipulaguna, Nisal and Zhou, Chenhao and Hughes, Maria Celia B and Soyer, H Peter and von Schuckmann, Lena and Khosrotehrani, Kiarash},
  title = {Beta‐Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random‐Effects Meta‐Analysis},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  volume = {38},
  number = {1},
  doi = {10.1111/pcmr.13225}
}
Kostenlos starten →